10/637,099 Search 1

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAYLC1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05   CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14   2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14   2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14   CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21   IPC search and display fields enhanced in CA/CAplus with the
                   IPC reform
 NEWS  8  DEC 23   New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                   USPAT2
 NEWS  9  JAN 13   IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13   New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                   INPADOC
 NEWS 11  JAN 17   Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17   IPC 8 in the WPI family of databases including WPIFV

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:37:26 ON 27 JAN 2006

=> d
ENTER NAME OF ITEM TO BE DISPLAYED OR (?):
ENTER NAME OF ITEM TO BE DISPLAYED OR (?):end

=> file registry
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21
```

FILE 'REGISTRY' ENTERED AT 13:37:46 ON 27 JAN 2006

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JAN 2006 HIGHEST RN 872781-89-0
DICTIONARY FILE UPDATES: 26 JAN 2006 HIGHEST RN 872781-89-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10637099\10637099b.str



chain nodes :
6 7 14 15 16 17 18 19 20
ring nodes :
1 2 3 4 5 8 9 10 11 12 13
chain bonds :
1-6 3-8 4-7 11-14 14-15 15-16 15-17 16-18 18-19 19-20
ring bonds :
1-2 1-5 2-3 3-4 4-5 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 4-7 11-14 14-15 15-17 16-18 18-19 19-20
exact bonds :
3-8 15-16
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:38:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

```
100.0% PROCESSED         2 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            2 TO      124
PROJECTED ANSWERS:               2 TO      124

L2             2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:38:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       58 TO ITERATE

100.0% PROCESSED        58 ITERATIONS                                57 ANSWERS
SEARCH TIME: 00.00.01

L3             57 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   167.38     167.59

FILE 'CAPLUS' ENTERED AT 13:38:55 ON 27 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 27 Jan 2006  VOL 144 ISS 6
FILE LAST UPDATED: 26 Jan 2006  (20060126/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4             2 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:143100 CAPLUS
DOCUMENT NUMBER: 140:199315
TITLE: Preparation of iminothiazolidinone amino acid derivatives as inhibitors of HCV replication
INVENTOR(S): Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao, Min; Colonno, Richard
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014852	A2	20040219	WO 2003-US24717	20030808
WO 2004014852	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005069522	A1	20050331	US 2003-637156	20030808
US 2005096364	A1	20050505	US 2003-637099	20030808
PRIORITY APPLN. INFO.:			US 2002-402661P P	20020812
			US 2002-403694P P	20020815

OTHER SOURCE(S): MARPAT 140:199315
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I [R1 = C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aryloxy, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C1-C6)alkoxy, etc.; R2, R3 = independently C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aryloxy, heterocyclyl, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C1-C6)alkoxy, etc., with the proviso that one of R2 or R3 can be a bond and R2 and R3 are joined to form a cyclic structure; R4 = C1-C4 alkyl, optionally substituted with 1-3 halo, 1-3 oxygen, or 1-3 nitrogen, said R4 having an S stereoconfiguration; R5 = H or a bond wherein R4 and R5 are joined to form a cyclic structure] were prepared as inhibitors of HCV replication. Thus, reaction of 5-(4-aminophenyl)-2-(3-fluorophenylimino)-3-furan-2-ylmethylthiazolidin-4-one (preparation given) with

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-59-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-[(5-methylpyrazinyl)methyl]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-67-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
N-benzyloxycarbonyl-L-alanyl chloride gave compd. II. The prepd. compds. were assayed for the inhibition of HCV replicon cell line and were classified with activity of EC50 < 0.1 μM, 0.1 μM ≤ EC50 ≤ 1 μM, 1 μM ≤ EC50 ≤ 5 μM, or EC50 ≥ 5 μM.
IT 657412-48-1P 657412-56-1P 657412-59-4P 657412-67-4P 657412-73-2P 657412-89-0P 657412-91-4P 657412-93-6P 657412-95-8P 657412-97-0P 657412-99-2P 657413-00-8P 657413-01-9P 657413-02-0P 657413-05-3P 657413-07-5P 657413-09-7P 657413-10-0P 657413-12-2P 657413-15-5P 657413-17-7P 657413-19-9P 657413-23-5P 657413-25-7P 657413-27-9P 657413-29-1P 657413-31-5P 657413-33-7P 657413-35-9P 657413-38-2P 657413-40-6P 657413-41-7P 657413-44-0P 657413-46-2P 657413-48-4P 657413-52-0P 657413-54-2P 657413-56-4P 657413-58-6P 657413-64-4P 657413-65-5P 657413-68-8P 657413-71-3P 657413-74-6P 657413-83-7P 657413-84-8P 657413-92-8P 657413-93-9P 657413-94-0P 657413-95-1P 657413-96-2P 657413-97-3P 657413-98-4P 657414-05-6P 657414-06-7P 657414-13-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)
RN 657412-48-1 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-56-1 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-73-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-(8-isoquinolinylimino)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-89-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(2-phenoxyethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-91-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[(tetrahydro-1,1-dioxido-3-thienyl)methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-93-6 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Double bond geometry unknown.



RN 657412-99-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[(tetrahydro-2-furanyl)methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-00-8 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(3-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-95-8 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[2-(2-thienyl)ethyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-97-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[[3-(trifluoromethoxy)phenyl]methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 657413-01-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(3-fluorophenyl)imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-02-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[(2,3,4-trifluorophenyl)methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-05-3 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-4-oxo-2-[(3-phenoxyphenyl)imino]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-07-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-ethylphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-09-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2,3-dihydro-1H-inden-5-yl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-10-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2-chloro-4-methylphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-12-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3,5-difluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-15-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[4-(1-methylpropyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-17-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-cyano-5-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-19-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[2-methoxy-5-(trifluoromethyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-23-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-chloro-4-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-29-1 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(4-fluoro-2-methylphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-31-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2-chloro-4-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-25-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-chlorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-27-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-4-oxo-2-[[3-(trifluoromethoxy)phenyl]imino]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-33-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-4-oxo-2-[[4-(trifluoromethyl)phenyl]imino]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-35-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-38-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluoro-4-methoxyphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-40-6 CAPLUS
CN Carbamic acid,
[(1S)-2-[[4-[2-[[4-fluoro-3-(trifluoromethyl)phenyl]imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-46-2 CAPLUS
CN Carbamic acid, methyl[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-48-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-[(3-fluorophenyl)methyl]-4-oxo-2-(3-pyridinylimino)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-41-7 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[3-[(5-methylpyrazinyl)methyl]-2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-44-0 CAPLUS
CN Carbamic acid,
[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-52-0 CAPLUS
CN Carbamic acid,
[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(3-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-54-2 CAPLUS
CN Carbamic acid,
[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(4-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-56-4 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[2-(methylimino)-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-58-6 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[3-methyl-4-oxo-2-[(2-pyridinylmethyl)imino]-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-68-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-71-3 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-64-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(ethoxycarbonyl)imino]-4-oxo-3-(3-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-65-5 CAPLUS
CN Carbamic acid,
[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-74-6 CAPLUS
CN Benzeneacetamide,
N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-83-7 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-(methylimino)-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-84-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-[[4-[4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-92-8 CAPLUS
CN Benzeneacetamide, α-hydroxy-N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-95-1 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-96-2 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-93-9 CAPLUS
CN Benzeneacetamide, α-methyl-N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-94-0 CAPLUS
CN Benzeneacetamide, α-methoxy-N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-97-3 CAPLUS
CN Benzenepropanamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-98-4 CAPLUS
CN Benzamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657414-05-6 CAPLUS
CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[[(phenylmethyl)amino]carbonyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657414-06-7 CAPLUS
CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[(phenylamino)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Absolute stereochemistry.
Double bond geometry unknown.





RN 657414-13-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **657414-29-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)
RN 657414-29-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2004:142910 CAPLUS
DOCUMENT NUMBER: 140:199742
TITLE: Preparation of iminothiazolidinone amino acid derivatives as combination pharmaceutical agents for use as inhibitors of HCV replication
INVENTOR(S): Colonno, Richard; Lemm, Julie; O'Boyle, Donald; Gao, Min; Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014313	A2	20040219	WO 2003-US25036	20030808
WO 2004014313	A3	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005069522	A1	20050331	US 2003-637156	20030808
US 2005096364	A1	20050505	US 2003-637099	20030808
PRIORITY APPLN. INFO.:			US 2002-402661P	P 20020812
			US 2002-403694P	P 20020815

OTHER SOURCE(S): MARPAT 140:199742
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound which is effective in inhibiting the function of the HCV NS5A protein and another compound having anti-HCV activity. Compds. which can inhibit the function of the NS5A protein have structure I [R1, R2, R3 are (cyclo)alkyl, aryl, alkoxy, aryloxy, arylalkyl, etc.; R4 is alkyl, optionally substituted by halogen, oxygen, or nitrogen; R2/R3 and R4/R5 can form rings] or their pharmaceutically-acceptable salt or prodrugs. Compds. having anti-HCV activity are selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, etc. Thus, compound II was prepared by reaction of 5-(4-aminophenyl)-2-[(3-fluorophenyl)imino]-3-(furan-2-ylmethyl)thiazolidin-4-one (preparation given) with N-(benzyloxycarbonyl)-L-alanyl chloride (Cbz-L-Ala-Cl) and showed EC50 = 0.1-1 μM in the HCV

replicon cell line assay.

IT 657412-48-1P 657412-56-1P 657412-59-4P
657412-67-4P 657412-73-2P 657412-89-0P
657412-91-4P 657412-93-6P 657412-95-8P
657412-97-0P 657412-99-2P 657413-00-8P
657413-01-9P 657413-02-0P 657413-05-3P
657413-07-5P 657413-09-7P 657413-10-0P
657413-12-2P 657413-15-5P 657413-17-7P
657413-19-9P 657413-23-5P 657413-25-7P
657413-27-9P 657413-29-1P 657413-31-5P
657413-33-7P 657413-35-9P 657413-38-2P
657413-40-6P 657413-41-7P 657413-44-0P
657413-46-2P 657413-48-4P 657413-52-0P
657413-54-2P 657413-56-4P 657413-58-6P
657413-64-4P 657413-65-5P 657413-68-8P
657413-71-3P 657413-74-6P 657413-83-7P
657413-84-8P 657413-92-8P 657413-93-9P
657413-94-0P 657413-95-1P 657413-96-2P
657413-97-3P 657413-98-4P 657414-05-6P
657414-06-7P 657414-13-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)

RN 657412-48-1 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-56-1 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 657412-73-2 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-(8-isoquinolinylimino)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-89-0 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(2-phenoxyethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

Double bond geometry unknown.



RN 657412-59-4 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-[(5-methylpyrazinyl)methyl]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-67-4 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-91-4 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[(tetrahydro-1,1-dioxido-3-thienyl)methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-93-6 CAPLUS

CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[[4-(trifluoromethoxy)phenyl]methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-95-8 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[2-(2-thienyl)ethyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657412-97-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[[3-(trifluoromethoxy)phenyl]methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 657413-01-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-[2-(3,4-dimethoxyphenyl)ethyl]-2-[(3-fluorophenyl)imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 1-A



Double bond geometry unknown.



RN 657412-99-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[(tetrahydro-2-furanyl)methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-00-8 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(3-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.

PAGE 2-A

RN 657413-02-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-[(2,3,4-trifluorophenyl)methyl]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-05-3 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-4-oxo-2-[(3-phenoxyphenyl)imino]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-07-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-ethylphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-09-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2,3-dihydro-1H-inden-5-yl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-15-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[4-(1-methylpropyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-17-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-cyano-5-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-10-0 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2-chloro-4-methylphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-12-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3,5-difluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-19-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[2-methoxy-5-(trifluoromethyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-23-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-chloro-4-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-25-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-chlorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-27-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-4-oxo-2-[(3-(trifluoromethoxy)phenyl]imino]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-33-7 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-(2-furanylmethyl)-4-oxo-2-[[4-(trifluoromethyl)phenyl]imino]-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-35-9 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-29-1 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(4-fluoro-2-methylphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-31-5 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(2-chloro-4-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-38-2 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluoro-4-methoxyphenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-40-6 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(4-fluoro-3-(trifluoromethyl)phenyl]imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-41-7 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[3-[(5-methylpyrazinyl)methyl]-2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-44-0 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-(2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-52-0 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-(2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(3-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-54-2 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(4-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-46-2 CAPLUS
CN Carbamic acid, methyl[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-48-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[3-[(3-fluorophenyl)methyl]-4-oxo-2-(3-pyridinylimino)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-56-4 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[2-(methylimino)-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-58-6 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[3-methyl-4-oxo-2-[(2-pyridinylmethyl)imino]-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-64-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(ethoxycarbonyl)imino]-4-oxo-3-(3-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-65-5 CAPLUS
CN Carbamic acid, [(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-74-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-83-7 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-(methylimino)-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-68-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-71-3 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-84-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-1-methyl-2-[[4-[2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-92-8 CAPLUS
CN Benzeneacetamide, α-hydroxy-N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-93-9 CAPLUS
CN Benzeneacetamide, α-methyl-N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-94-0 CAPLUS
CN Benzeneacetamide, α-methoxy-N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-97-3 CAPLUS
CN Benzenepropanamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-98-4 CAPLUS
CN Benzamide,
N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-95-1 CAPLUS
CN Benzeneacetamide,
N-[(1S)-1-methyl-2-[[4-[2-[(1-methylethyl)imino]-4-oxo-3-(2-pyridinylmethyl)-5-thiazolidinyl]phenyl]amino]-2-oxoethyl]-α-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657413-96-2 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657414-05-6 CAPLUS
CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[[(phenylmethyl)amino]carbonyl]amino]-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657414-06-7 CAPLUS
CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[(phenylamino)carbonyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 657414-13-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-[[4-[3-(2-furanylmethyl)-2-[[4-(4-morpholinyl)phenyl]imino]-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT **657414-29-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)
RN 657414-29-4 CAPLUS
CN Carbamic acid, [(1S)-2-[[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]amino]-1-methyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



=>
Uploading C:\Program Files\Stnexp\Queries\10637099\10637099c.str



chain nodes :
7 8 9 10 11 12 13
ring nodes :
1 2 3 4 5 6 14 15 16 17 18
chain bonds :
1-14 4-7 7-8 8-9 8-10 9-11 11-12 12-13
ring bonds :
1-6 1-2 2-3 3-4 4-5 5-6 14-15 14-18 15-16 16-17 17-18
exact/norm bonds :
1-14 4-7 7-8 8-10 9-11 11-12 12-13 14-15 14-18 15-16 16-17 17-18
exact bonds :
8-9
normalized bonds :
1-6 1-2 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
   REGlstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 13:47:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 2 TO 124

L6 2 SEA SSS SAM L1

L7 2 L6

=> s l5
   REGlstRY INITIATED

```
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



SAMPLE SEARCH INITIATED 13:47:46 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       29 TO ITERATE

100.0% PROCESSED       29 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          257 TO      903
PROJECTED ANSWERS:               3 TO      163

L8             3 SEA SSS SAM L5



L9             2 L8

=> s l5 full
   REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.



FULL SEARCH INITIATED 13:59:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      568 TO ITERATE

100.0% PROCESSED      568 ITERATIONS                               59 ANSWERS
SEARCH TIME: 00.00.01

L10            59 SEA SSS FUL L5



L11            2 L10

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.46     362.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -1.50

FILE 'CAPLUS' ENTERED AT 14:00:35 ON 27 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 27 Jan 2006 VOL 144 ISS 6
FILE LAST UPDATED: 26 Jan 2006 (20060126/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10
L12 2 L10

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	364.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.50

STN INTERNATIONAL LOGOFF AT 14:02:05 ON 27 JAN 2006

10/637,099 Search 2

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:SSPTAYLC1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05   CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14   2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14   2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14   CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21   IPC search and display fields enhanced in CA/CAplus with the
                   IPC reform
 NEWS  8  DEC 23   New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                   USPAT2
 NEWS  9  JAN 13   IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13   New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                   INPADOC
 NEWS 11  JAN 17   Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17   IPC 8 in the WPI family of databases including WPIFV

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:03:01 ON 27 JAN 2006

=> ile registry
ILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:03:11 ON 27 JAN 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JAN 2006 HIGHEST RN 872781-89-0
DICTIONARY FILE UPDATES: 26 JAN 2006 HIGHEST RN 872781-89-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10637099\10637099d.str



chain nodes :
7 8 9 10 11 12 13 14
ring nodes :
1 2 3 4 5 6

chain bonds :
1-14 4-7 7-8 8-9 8-10 9-11 11-12 12-13
ring bonds :
1-6 1-2 2-3 3-4 4-5 5-6
exact/norm bonds :
1-14 4-7 7-8 8-10 9-11 11-12 12-13
exact bonds :
8-9
normalized bonds :
1-6 1-2 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 14:03:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 6561 TO ITERATE

30.5% PROCESSED 2000 ITERATIONS 31 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 126364 TO 136076
PROJECTED ANSWERS: 1428 TO 2638

L2 31 SEA SSS SAM L1

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.88       1.09

FILE 'CAPLUS' ENTERED AT 14:04:06 ON 27 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Jan 2006  VOL 144 ISS 6
FILE LAST UPDATED: 26 Jan 2006  (20060126/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3          24 L2

=> d his

     (FILE 'HOME' ENTERED AT 14:03:01 ON 27 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 14:03:11 ON 27 JAN 2006
L1              STRUCTURE UPLOADED
L2           31 S L1

     FILE 'CAPLUS' ENTERED AT 14:04:06 ON 27 JAN 2006
L3           24 S L2

=> d ibib abs hitstr 10-24
```

L3 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:465965 CAPLUS
DOCUMENT NUMBER: 137:47128
TITLE: Preparation of of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders and tumors.
INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048099	A1	20020620	WO 2001-EP13545	20011121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10063008	A1	20020620	DE 2000-10063008	20001216
CA 2431766	AA	20020620	CA 2001-2431766	20011121
AU 2002021881	A5	20020624	AU 2002-21881	20011121
EP 1341755	A1	20030910	EP 2001-270524	20011121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016115	A	20031223	BR 2001-16115	20011121
JP 2004515538	T2	20040527	JP 2002-549632	20011121
NO 2003002695	A	20030613	NO 2003-2695	20030613
US 2004038858	A1	20040226	US 2003-450651	20030616
ZA 2003005455	A	20040826	ZA 2003-5455	20030715
US 2005137230	A1	20050623	US 2005-59655	20050217

PRIORITY APPLN. INFO.:
DE 2000-10063008 A 20001216
WO 2001-EP13545 W 20011121
US 2003-450651 A3 20030616

OTHER SOURCE(S): MARPAT 137:47128
AB DNHCOXCHR1CONH(CH2)nEW [D = (substituted) Ph, pyridyl; R1 = H, Ar, Het, cycloalkyl, (substituted) A; R2 = H, A; E = (substituted) phenylene, piperidin-1,4-diyl; W = Ar, Het, N(R2)2, R2, cycloalkyl; X = NH, O; A = (fluoro-substituted) (O-, S-, or CH:CH-interrupted) alkyl; Ar = (substituted) Ph; Het = (aromatic) (substituted) heterocyclyl; n = 0, 1], were prepared Thus, Z-D-Phe-OH, 2'-methylsulfonylbiphenyl-4-ylamine, N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride, 1-hydroxybenzotriazole, and 4-methylmorpholine were stirred 40 h in DMF to give benzyl [(R)-1-(2'-methylsulfonylbiphenyl-4-ylcarbamoyl)-2-phenylethyl]carbamate. This was hydrogenolyzed in MeOH over Pd/C and the

L3 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
product was stirred with 4-chlorophenyl isocyanate in CH2Cl2 to give (R)-2-[3-(4-chlorophenyl)ureido]-N-(2'-methylsulfonylbiphen-4-yl)-3-phenylpropionamide. The latter inhibited factor Xa with IC50 = 8.6 + 10-8 M.
IT 438054-08-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)
RN 438054-08-1 CAPLUS
CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



IT 438055-90-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)
RN 438055-90-4 CAPLUS
CN Benzenepropanamide, α-[[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L3 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:368463 CAPLUS
DOCUMENT NUMBER: 136:386109
TITLE: Preparation of amide derivatives as antiherpes agents
INVENTOR(S): Kontani, Toru; Miyata, Junji; Hamaguchi, Wataru; Miyazaki, Yoji; Suzuki, Hiroshi; Nakai, Eiichi; Kageyama, Shunji
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Rational Drug Design Laboratories
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038554	A1	20020516	WO 2001-JP9790	20011108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2428184	AA	20020516	CA 2001-2428184	20011108
AU 2002012734	A5	20020521	AU 2002-12734	20011108
EP 1340750	A1	20030903	EP 2001-981033	20011108
EP 1340750	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 302197	E	20050915	AT 2001-981033	20011108
US 2004034232	A1	20040219	US 2003-416371	20030512
US 6949543	B2	20050927		

PRIORITY APPLN. INFO.:
JP 2000-344354 A 20001110
WO 2001-JP9790 W 20011108

OTHER SOURCE(S): MARPAT 136:386109
GI



I

AB The title compds. I [R1, R2 = H, alkyl, etc.; ring A = (un)substituted aryl, etc.; X = CO, SO2; R3 = (un)substituted cycloalkyl, etc.] are prepared
These amide derivs. are useful as drugs and antiviral agents, in particular, preventives or remedies for various diseases caused by the

L3 ANSWER 10 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
infection with herpesviruses, more specifically, various herpesvirus infections such as pox (blister) caused by the infection with varicella zoster virus, herpes zoster caused by the recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis caused by the infection with HSV-1 and genital herpes caused by the infection with HSV-2. N-({[4-(2-Aminothiazol-4-yl)phenyl]carbamoyl}methyl)-4-fluoro-N-(2,3-dihydro-1H-indol-6-yl)benzamide dihydrochloride showed EC50 value of 0.046 μM against varicella zoster virus, vs. EC50 value of 4.3 μM shown by acyclovir.

IT **425688-37-5P 425689-11-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amide derivs. as antiherpes agents)

RN 425688-37-5 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]tetrahydro-N-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 425689-11-8 CAPLUS
CN 2-Thiophenecarboxamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:660346 CAPLUS
DOCUMENT NUMBER: 135:226989
TITLE: Synthesis of thiazolyl-phenyl-amide derivatives used to inhibit herpes virus replication and treat herpes infection
INVENTOR(S): Crute, J. James; Faucher, Anne-marie; Grygon, Christine; Hargrave, Karl D.; Simoneau, Bruno; Thavonekham, Bounkham
PATENT ASSIGNEE(S): Boehringer Ingelheim Ltd., Can.; Boehringer Ingelheim Pharma KG
SOURCE: U.S., 61 pp., Cont.-in-part of U.S. Ser. No. 759,201.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 6288091	B1	20010911	US 1999-364446		19990730
CN 1207094	A	19990203	CN 1996-199443		19961204
US 6057451	A	20000502	US 1996-759201		19961204
ZA 9610850	A	19970630	ZA 1996-10850		19961223
US 6348477	B1	20020219	US 1999-456857		19991208
US 6458959	B1	20021001	US 2000-685686		20001010
PRIORITY APPLN. INFO.:			US 1995-9433P	P	19951229
			US 1996-23209P	P	19960802
			US 1996-759201	A	19961204
			US 1999-456857	A3	19991208

OTHER SOURCE(S): MARPAT 135:226989
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = H, alkyl(amino), amino, alkanoylamino, etc.; Z = NR2-C(O)-Q-CH(R3)-NR4R5; R2 = H, alkyl; Q = bond, CH2; R3 = H, ((substituted)phenyl)alkyl; R4 = H, ((substituted)phenyl)alkyl, indanyl, cycloalkyl-alkyl; R5 = (Het)-(Y)-(alkyl)-C(O); Het = pyridinyl; Y = O, S] were prepared Over 200 synthetic examples were disclosed. For instance, Boc-glycine was N-benzylated (NaH, PhCH2Br, THF, reflux, 16 h) and the product converted to II (i-BuOCOCl, Et3N, DCM, 4'-aminoacetophenone, room temperature, 16 h.). Amide II was converted to example compound III (n = 0, P = Boc, E = CH2Ph) (I2, thiourea, IPA, reflux, 2.5 h.). III (n = 0, P = CH2Ph, E = C:OPh) had IC50 = 0.072 μM for HSV-1 and EC50 = 0.007 μM for human cytomegalovirus. I are used for treating herpes infection by inhibiting the herpes helicase-primase enzyme complex.

IT **193346-89-3P 193347-45-4P 359713-63-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of thiazolyl-phenyl-amide derivs. used to inhibit

L3 ANSWER 12 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
herpes virus replication and treat herpes infection)

RN 193346-89-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 193347-45-4 CAPLUS
CN 3-Pyridineacetamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 359713-63-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]-N-[(3-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:441778 CAPLUS
DOCUMENT NUMBER: 133:75333
TITLE: Fluorescent dyes for solid phase and solution phase screening
INVENTOR(S): Auer, Manfred; Gstach, Hubert
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037448	A1	20000629	WO 1999-EP10126	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6207831	B1	20010327	US 1998-217795	19981221
CA 2356344	AA	20000629	CA 1999-2356344	19991220
EP 1140856	A1	20011010	EP 1999-964612	19991220
EP 1140856	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533329	T2	20021008	JP 2000-589520	19991220
AT 294164	E	20050515	AT 1999-964612	19991220
US 2001005752	A1	20010628	US 2001-754958	20010105
US 2005227299	A1	20051013	US 2005-139753	20050527
PRIORITY APPLN. INFO.:			US 1998-217795	A 19981221
			WO 1999-EP10126	W 19991220
			US 2001-754958	A1 20010105

OTHER SOURCE(S): MARPAT 133:75333
GI



I

AB The fluorescent dyes suitable for various methods of solid phase and solution
phase organic chemical for synthesis of mols., useful inn fluorescence based
processes for the identification of inhibitors of mol. interactions and for the identification of mols. which bind to target macromols. like peptides proteins, nucleic acids, carbohydrates etc., has a structure I wherein one of R2 and R2 and one of R3 and R4 is hydrogen and another is -COOH, -COOR7, -CONH2, -CONR8R9, NR10R11, etc., one of R5 and R6 is hydrogen and another is hydrogen, halogen, NO2, NR10R11, NHCOR12, etc., R7
is carboxyl protecting or carboxyl activating group, R8 or R9 is hydrogen and another is C1-C4 alkyl, Ph, benzyl, etc., R10 and R11 are independently hydrogen, C1-C4 alkyl, or amino protecting group, R12 is ((substituted) C1-C10) alkyl or Ph. Thus benzophenone was reacted with 4-Hydrazino-benzoic acid in methanol for 50 h, then with lead tetraacetate
for 30-60 min., followed by treatment with boron-trifluoride etherate to give (3-phenyl-1H-indazol-1-yl)benzoic acid, which showing λmax (absorption) 328 nm ε=22569 M-1·cm, λmax (emission) 396 nm, and λmax (excitation) 328 nm.

IT **279249-50-2P**
RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(fluorescent dyes for solid phase and solution phase screening)

RN 279249-50-2 CAPLUS

CN Benzoic acid, 4-[3-[4-[[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]-1H-indazol-1-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:351518 CAPLUS
DOCUMENT NUMBER: 133:4650
TITLE: Preparation of heteroaryl-substituted aromatic compounds as antiherpes compounds
INVENTOR(S): Simoneau, Bruno; Crute, James J.; Faucher, Anne-Marie; Grygon, Christine A.; Hargrave, Karl D.; Thavonekham, Bounkham
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000029399	A1	20000525	WO 1999-CA1066	19991109
W: CA, JP, MX, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1998-108272P	P 19981112

OTHER SOURCE(S): MARPAT 133:4650
GI



II



III

AB The title compds. X-Aryl-Y-Z [I; X = 5-6 membered aromatic heterocycle; Aryl
= (un)substituted Ph, pyridyl; Y is absent or a bridging group, for example NHC(O)CH2; Z is a terminal group, for example NHCO2t-Bu or II], which inhibit the herpes helicase-primase enzyme, rendering the compds. useful as antiviral agents, were prepared E.g., a multi-step synthesis of
benzamide III was presented. Biol. data (IC50 and/or EC50 against HSV-1 and HCMV) for compds. I were given.

IT **270565-94-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heteroaryl-substituted arom. compds. as antiherpes compds.)

RN 270565-94-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[(1S)-2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-1-(cyclohexylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:314540 CAPLUS
DOCUMENT NUMBER: 132:334477
TITLE: Preparation of compounds derived from an amine nucleus as inhibitors of IMPDH enzyme
INVENTOR(S): Liu, Chunjian; Dhar, T. G. Murali; Gu, Henry H.; Iwanowicz, Edwin J.; Leftheris, Katerina; Pitts, William John
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000025780	A1	20000511	WO 1999-US24825	19991022
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2348234	AA	20000511	CA 1999-2348234	19991022
EP 1126843	A1	20010829	EP 1999-955142	19991022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 764479	B2	20030821	AU 2000-11315	19991022
PRIORITY APPLN. INFO.:			US 1998-106186P	P 19981029
			WO 1999-US24825	W 19991022

OTHER SOURCE(S): MARPAT 132:334477
GI



II

AB The title compds. XN(R)BD [I; X = (un)substituted monocyclic or bicyclic ring system optionally containing up to 4 heteroatoms selected from N, O, and S; R = H, alkyl; B = (un)substituted monocyclic or bicyclic ring system optionally containing up to 4 heteroatoms selected from N, O, and S; D = (un)substituted monocyclic or bicyclic ring system optionally containing up to

L3 ANSWER 15 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
4 heteroatoms selected from N, O, and S), useful in treating or preventing
IMPDH (inosine-5'-monophosphate dehydrogenase) mediated diseases, such as transplant rejection and autoimmune diseases, were prepd. E.g., a multi-step synthesis of triazole II was given. Compds. I are effective at
0.1-500 mg/kg/day.
IT **267647-88-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of compds. derived from an amine nucleus as inhibitors of IMPDH enzyme)
RN 267647-88-1 CAPLUS
CN Benzamide, N-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-2-oxoethyl]-(9CI)
(CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:98525 CAPLUS
DOCUMENT NUMBER: 132:137396
TITLE: Phenylazole compounds, process for producing the same and drugs for hyperlipemia
INVENTOR(S): Umeda, Nobuhiro; Mochizuki, Nobuo; Uchida, Seiichi; Nishibe, Tadayuki; Yamada, Hirokazu; Ito, Kunihito; Horikoshi, Hiromi
PATENT ASSIGNEE(S): Nippon Soda Co., Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006550	A1	20000210	WO 1999-JP4070	19990729
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339123	AA	20000210	CA 1999-2339123	19990729
AU 9949297	A1	20000221	AU 1999-49297	19990729
AU 753360	B2	20021017		
EP 1101759	A1	20010523	EP 1999-933152	19990729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1131217	B	20031217	CN 1999-809019	19990729
JP 2000290280	A2	20001017	JP 1999-216581	19990730
JP 2000281656	A2	20001010	JP 1999-221789	19990804
JP 2000281658	A2	20001010	JP 1999-221790	19990804
US 6342516	B1	20020129	US 2001-744786	20010126
PRIORITY APPLN. INFO.:			JP 1998-218316	A 19980731
			JP 1998-222157	A 19980805
			JP 1999-16846	A 19990126
			JP 1999-19670	A 19990128
			JP 1999-24318	A 19990201
			WO 1999-JP4070	W 19990729

OTHER SOURCE(S): MARPAT 132:137396
GI

L3 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II



III

AB Phenylpyrazole and phenylimidazole compds. represented by general formula (I; wherein A represents (un)substituted imidazolyl or pyrazolyl; B represents (un)substituted (CH2)k or (CH:CH)k; Y = bond, O, S, SO2, CO, OCH2, C1-5 alkyl-(un)substituted NHCO or NH; Z = (un)substituted and saturated
or unsatd. heterocycle containing 1 to 4 N, O or S atoms, (un)substituted benzoquinonyl or naphthoquinonyl) or pharmaceutically acceptable salts thereof are prepared Claimed are drugs for hyperlipemia which contain these
compds. I as the active ingredient. Among all, compds. wherein Z is substituted chroman-2-yl, 2,3-dihydrobenzofuran-2-yl, etc. have an effect of inhibiting the formation of lipid peroxides too. Thus, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, 1-(4-aminophenyl)imidazole 4.0, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride 2.82, 1-hydroxybenzotriazole 2.72 g, and 2.5 mL Et3N were added to 30 mL DMF and stirred at room temperature for 20 h to
give title compound (II). II and N-[4-(imidazol-1-yl)phenyl]-1-methyl-3-pyrrrolecarboxamide (III) at 25 mg/kg p.o. lowered total serum level of cholesterol 40 and 75%, resp., and serum triglyceride level by 62 and 91%,
resp. A tablet formulation containing I was prepared
IT **256660-58-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylazole compds. as hypolipidemics and inhibitors of
lipid peroxide formation)
RN 256660-58-9 CAPLUS
CN 2H-1-Benzopyran-2-carboxamide, 3,4-dihydro-6-hydroxy-N-[2-[[4-(1H-imidazol-1-yl)phenyl]amino]-2-oxoethyl]-N,2,5,7,8-pentamethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:549264 CAPLUS
DOCUMENT NUMBER: 131:184944
TITLE: Preparation of phenyl and aryl-fused thiazole derivatives as antiviral agents for suppression and treatment of herpes family viral infections and sexually-transmitted viral diseases
INVENTOR(S): Flygare, John A.; Jaen, Juan C.; Kearney, Patrick C.; Medina, Julio C.; Sivaraja, Mohanram
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942455	A1	19990826	WO 1999-US2947	19990210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932892	A1	19990906	AU 1999-32892	19990210
PRIORITY APPLN. INFO.:			US 1998-75224P P	19980219
			WO 1999-US2947 W	19990210

OTHER SOURCE(S): MARPAT 131:184944
GI



I II

AB Ph and aryl-fused thiazole derivs. (I) [where X = S, O, NH, or N-lower alkyl; Y = (un)substituted CH or N; or XY = triat. divalent unit of CH, C-alkyl, and N (3 subunits may not all be N); R1 = H, lower alkyl, or taken together with Y forms a 5- or 6-membered ring; R2, R3, and R4 = independently H, (hetero)alkyl, (hetero)arylalkyl, halogen, CN, NO2, (aryl)alkoxy, (un)substituted sulfamoyl, (un)substituted amino, OH, etc.; R5 = H, lower (aryl)alkyl, aryl, (un)substituted amino; with provisos] were prepared as antiviral agents useful in the suppression and treatment of sexually-transmitted viral diseases and herpes family viral infections,

L3 ANSWER 17 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

esp. HSV1, HSV2, Epstein Barr virus, and varicella zoster virus. Thus, 2-iodophenacyl bromide was added to thiourea in dioxane and stirred at room temp. for eight hours to yield 2-amino-4-(2-iodophenyl)thiazole (II).

Nine compds. of the invention were tested for antiviral activity using an HSV-1 gel primase assay and exhibited IC50 values ranging from 5 μM to 100 μM.

IT **240136-53-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph and aryl-fused thiazole derivs. as antiviral agents for herpes family viral infections and sexually-transmitted viral diseases)

RN 240136-53-2 CAPLUS
CN Cyclohexanecarboxamide, N-[2-[[4-(2-amino-5-methyl-4-thiazolyl)-2-(trifluoromethyl)phenyl]amino]-2-oxoethyl]-N-[(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1997:543457 CAPLUS
DOCUMENT NUMBER: 127:149142
TITLE: Preparation of 4-(aminothiazolyl)acetanilides and analogs as antiherpes agents
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharmaceuticals, Inc., USA; Boehringer Ingelheim (Canada) Ltd.
SOURCE: PCT Int. Appl., 336 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724343	A1	19970710	WO 1996-US19131	19961204
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9716828	A1	19970728	AU 1997-16828	19961204
EP 871619	A1	19981021	EP 1996-945567	19961204
EP 871619	B1	20021106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1207094	A	19990203	CN 1996-199443	19961204
BR 9612435	A	19990713	BR 1996-12435	19961204
JP 2000502702	T2	20000307	JP 1997-524325	19961204
NZ 331104	A	20000327	NZ 1996-331104	19961204
AT 227279	E	20021115	AT 1996-945567	19961204
ES 2186811	T3	20030516	ES 1996-945567	19961204
CA 2192433	AA	19970630	CA 1996-2192433	19961209
ZA 9610850	A	19970630	ZA 1996-10850	19961223
NO 9802950	A	19980625	NO 1998-2950	19980625
US 6458959	B1	20021001	US 2000-685686	20001010
PRIORITY APPLN. INFO.:			US 1995-9433P P	19951229
			US 1996-23209P P	19960802
			US 1996-759201 A3	19961204
			WO 1996-US19131 W	19961204
			US 1999-456857 A3	19991208

OTHER SOURCE(S): MARPAT 127:149142
AB 4-RC6H4R1 [I; R = (un)substituted 4-thiazolyl; R1 = NR2CO2lCHR3NR4R5, NR2aCO2NR3aR4a, etc.; R2,R2a = H or alkyl; R3 = H, alkyl, (un)substituted phenyl(alkyl); R3a = H, (cyano)alkyl, CH2CH2OH, phenyl(alkyl), etc.; R4 = H, alkyl, phenylalkyl, heterocyclyl, etc.; R4a = alkyl, phenyl(alkyl), etc.; R3R4 = atoms to form a ring; NR3aR4a = heterocyclyl; R5 = alkyl, phenyl(alkyl), heterocyclyl, etc.; Z1 = bond or CH2; Z2 = bond or CO] were prepared for treating herpes infections by inhibiting the herpes helicase-primase enzyme complex. Thus, Me3CO2CNHCH2CO2H was N-alkylated

L3 ANSWER 18 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
by PhCH2Br and the product amidated by 4-(H2N)C6H4COMe to give, after cyclocondensation with H2NCSNH2 and deprotection, I (R = 2-amino-4-thiazolyl, R1 = NHCOCH2NHCH2Ph). Data for biol. activity of I were given.
IT **193346-89-3P 193347-45-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(aminothiazolyl)acetanilides and analogs as antiherpes agents)
RN 193346-89-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 193347-45-4 CAPLUS
CN 3-Pyridineacetamide, N-[2-[[4-(2-amino-4-thiazolyl)phenyl]amino]-2-oxoethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L3 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:409957 CAPLUS
DOCUMENT NUMBER: 121:9957
TITLE: Energy transfer in β-turned peptide-bridged porphyrin dimers
AUTHOR(S): Tamiaki, Hitoshi; Nomura, Kimiatsu; Maruyama, Kazuhiro
CORPORATE SOURCE: Fac. Sci. Eng., Ritsumeikan Univ., Kyoto, 603-77, Japan
SOURCE: Bulletin of the Chemical Society of Japan (1993), 66(10), 3062-8
CODEN: BCSJA8; ISSN: 0009-2673
DOCUMENT TYPE: Journal
LANGUAGE: English
AB β-Turned peptide-bridged diporphyrinyl compds. were prepared Each of the isomeric monozinc complexes were easily available; metal-free porphyrin-peptide-Zn porphyrin and Zn porphyrin-peptide-metal-free porphyrin. In the isomers, the intramol. energy transfer efficiencies from Zn porphyrin moiety to metal-free porphyrin moiety were the same from anal. of the steady-state fluorescence spectra, indicating that the efficiencies should be independent upon the linked peptide spacer and dependent upon the distance between the porphyrin moieties in the mol. Singlet energy might migrate intramolecularly from the Zn porphyrin moiety to the metal-free one mainly by through-space mechanism.
IT **155279-49-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, complexation of, with zinc and absorption spectra of)
RN 155279-49-5 CAPLUS
CN Glycinamide, 1-[4-[10,15,20-tris(4-methylphenyl)-21H,23H-porphin-5-yl]benzoyl]-D-prolyl-N-[4-[10,15,20-tris(4-methylphenyl)-21H,23H-porphin-5-yl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



L3 ANSWER 19 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



PAGE 2-B



L3 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:536786 CAPLUS
DOCUMENT NUMBER: 115:136786
TITLE: Preparation of peptide p-pyridazinylanilides as cardiovascular agents.
INVENTOR(S): Bru-Magniez, Nicole; Nicolai, Eric; Teulon, Jean Marie
PATENT ASSIGNEE(S): Laboratoires UPSA S. A., Fr.
SOURCE: Fr. Demande, 73 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2646853	A1	19901116	FR 1989-6066	19890509
PRIORITY APPLN. INFO.:			FR 1989-6066	19890509

OTHER SOURCE(S): MARPAT 115:136786
GI



I

Q

AB The title compds. I [R1 = H, alkyl; R2 = H, alkyl, aralkyl, halo, OH, etc.; R3 = H, alkyl; or R2R3 = CH2(XH2)nCH2; n = 1-4; A = pyrrolidinediyl, etc.; B = CHR4X; R4 = H, alkyl, amino; X = CH2SH, CH2SAc, etc.] and their pharmaceutically acceptable salts, useful as cardiotonics, vasodilators, blood platelet aggregation inhibitors, and angiotensin converting enzyme inhibitors, were prepared Amidation of Z-Pro-Phe-OH (Z = PhCH2O2C) with pyridazinylaniline QH (preparation given), the resulting dipeptide amide Z-Pro-Phe-Q deprotected, and then condensed with AcSCH2CHMeCOCl in CH2Cl2 containing Et3N to give the title compound AcSCH2CHMeCO-Pro-Phe-Q (II). In an in vitro experiment using guinea pig heart, II at 7.9 + 10-6 M effected 50% of the maximum inotropic augmentation.

IT **135809-04-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as cardiovascular agent)

RN 135809-04-0 CAPLUS
CN L-Leucinamide, N-[1-(ethoxycarbonyl)-3-methylbutyl]-L-alanyl-L-prolyl-N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]- (9CI) (CA INDEX

L3 ANSWER 20 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

Absolute stereochemistry.



IT **135809-27-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for peptides as cardiovascular agents)

RN 135809-27-7 CAPLUS
CN Carbamic acid, [2-oxo-1-phenyl-2-[[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L3 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:632187 CAPLUS
DOCUMENT NUMBER: 107:232187
TITLE: Peptide derivatives for enzyme activity measurement
INVENTOR(S): Sasaki, Michiro; Ishijima, Cheko; Irie, Yasuo; Yasuda, Naohiko; Nishiyama, Kimiko; Matoba, Katsumoto; Watanabe, Junzo
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan; Kokusai Shiyaku K. K.
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62122599	A2	19870603	JP 1986-152093	19860628
JP 07055942	B4	19950614		
PRIORITY APPLN. INFO.:			JP 1985-167129	A1 19850729

GI



I

AB Peptides I (R = H, amino protecting group; A1 = phenylalanyl, leucyl, isoleucyl, etc.; A2 = phenylalanyl, valyl, prolyl, etc.; A3 = arginyl, lysyl; m, n = 0, 1) are substrates for enzyme activity determination A sample containing thrombin was treated with a reagent containing H-D-Phe-Pro-Arg-MA (MA = 4-morpholinoaniline) at 37° for 5 min, followed by treatment with a reagent containing metaperiodic acid and N-ethyl-N-sulfopropylaniline at room temperature for 10 min and spectrometric anal. at 735 nm for the determination of thrombin.

IT **111544-55-9P**
RL: PREP (Preparation)
(preparation of, as substrate, for thrombin and other enzyme determination, morpholinoaniline release and determination in relation to)

RN 111544-55-9 CAPLUS
CN L-Lysinamide, D-leucyl-L-phenylalanyl-N-[4-(4-morpholinyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 21 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



●3 HCl

L3 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1982:142879 CAPLUS
DOCUMENT NUMBER: 96:142879
TITLE: Antibacterial amide compounds
INVENTOR(S): Haskell, Theodore H.; Hutt, Marland P., Jr.; Nicolaides, Ernest D.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 19,984, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4267180	A	19810512	US 1980-117318	19800131
PRIORITY APPLN. INFO.:			US 1979-19984 A2	19790312

OTHER SOURCE(S): CASREACT 96:142879
GI



I

III

AB Amoxicillins I (R = N-acylglycyl, N-acylalanyl, N-acylisobutyryl, N-acylprolyl, N-acylmethionyl, N-acylvalyl, N-acylleucyl, N-acylglutaminyl, N-acyltyrosyl; R1 = Ph, 4-HOC6H4, 2-thienyl, 1,4-cyclohexadienyl), useful as bactericides, were prepared by treating amoxicillin (II) with imidazolide III. Thus, treating II Me2SO complex in DMF with III (R = N-acetylglycyl) in the presence of Et3N 2.5 h at room temperature gave I (R = N-acetylglycyl, R1 = 4-HOC6H4), isolated as the Na salt.

IT **79896-65-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 79896-65-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[2-[4-[[2-(acetylamino)-1-oxopropyl]amino]phenyl]-1,4-dihydro-4-oxo-5-pyrimidinyl]carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β[S*(R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 22 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L3 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:550681 CAPLUS
DOCUMENT NUMBER: 95:150681
TITLE: N-(6-[(Acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds and compositions containing them
INVENTOR(S): Haskell, Theodore Herbert; Schweiss, Dietrich; Mich, Thomas Frederick; Culbertson, Townley Payne
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: Eur. Pat. Appl., 86 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 15771	A1	19800917	EP 1980-300736	19800311
EP 15771	B1	19840606		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4311698	A	19820119	US 1980-112655	19800131
DK 8001037	A	19800913	DK 1980-1037	19800311
AU 8056341	A1	19800918	AU 1980-56341	19800311
AU 530301	B2	19830707		
JP 55147292	A2	19801117	JP 1980-31478	19800311
ZA 8001423	A	19810325	ZA 1980-1423	19800311
ES 489400	A1	19810416	ES 1980-489400	19800311
CA 1147324	A1	19830531	CA 1980-347438	19800311
AT 7789	E	19840615	AT 1980-300736	19800311
ES 497149	A1	19811101	ES 1980-497149	19801126
PRIORITY APPLN. INFO.:			US 1979-19983 A	19790312
			US 1980-112655 A	19800131
			EP 1980-300736 A	19800311

GI

L3 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II



III

AB Cephalosporins I (R = amino acid or peptide residue; R1 = Ph, 4-HOC6H4, 2-thienyl, 1,4-cyclohexadienyl; R2 = OAc, O2CNH2, heterocyclylthio) were prepared Thus 4-AcNHC6H4COMe was treated with HCO2Et and NCCH2CONH2 and hydrolyzed to give II which was treated with Ac-Ala-OH, converted to the imidazolide, and used to acylate the appropriate aminocephem to give III. III had a min. inhibitory concentration against Escherichia coli of 0.4 μg/mL.

IT **77004-11-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 77004-11-6 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[[[6-[4-[[2-(acetylamino)-1-oxopropyl]amino]phenyl]-1,2-dihydro-2-oxo-3-pyridinyl]carbonyl]amino]phenylacetyl]amino]-3-[(acetyloxy)methyl]-8-oxo-, monosodium salt, [6R-(6α,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 23 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of

L3 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1981:121570 CAPLUS
DOCUMENT NUMBER: 94:121570
TITLE: N-(2[(Acylaminoacylamino or aminoacylamino)phenyl)-4-hydroxy-5-pyrimidinylcarbonyl]cephalosporin compounds and compositions containing them
INVENTOR(S): Haskell, Theodore Herbert; Mich, Thomas Frederick; Sanchez, Joseph Peter; Schweiss, Dietrich
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: Eur. Pat. Appl., 81 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 15772	A1	19800917	EP 1980-300737	19800311
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
US 4311699	A	19820119	US 1980-112656	19800131
JP 55147291	A2	19801117	JP 1980-31476	19800311
PRIORITY APPLN. INFO.:			US 1979-19992 A	19790312
			US 1980-112656 A	19800131

GI



I



II



III

AB Cephalosporins I (R = amino acid or peptide residue; R1 = Ph, 4-HOC6H4, 2-thienyl, 1,4-cyclohexadienyl; R2 = OAc, O2CNH2, heterocyclylthio) were prepared Thus II was prepared by treating cephaloglycine with imidazolide III
and NaOH. III was prepared by treating 4-H2NC6H4C(:NH)NH2.2HCl with EtOCH:C(CO2Et)2, acylating the resulting aminophenylpyrimidinecarboxylic

L3 ANSWER 24 OF 24 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
acid with Ac-D-Ala-OH, and converting to the imidazolide. II had a min. inhibitory concn. against Pseudomonas of 3.1 μg/mL.

IT 76718-35-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 76718-35-9 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[[[2-[4-[[2-(acetylamino)-1-oxopropyl]amino]phenyl]-1,4-dihydro-4-oxo-5-pyrimidinyl]carbonyl]amino]phenylacetyl]amino]-3-[[(aminocarbonyl)oxy]methyl]-8-oxo-, monosodium salt, [6R-(6α,7β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● Na

PAGE 1-B

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	77.57	78.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.25	-11.25

STN INTERNATIONAL LOGOFF AT 14:05:08 ON 27 JAN 2006